Skip to content
Hair Pipeline
← Back to the pipeline

HMI-115

An injected antibody against the prolactin receptor — a hormone route nobody else is taking.

Phase 2InjectableBiologicProlactin receptor
Developed by
Hope Medicine
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Partners
Bayer
Indications
Androgenetic alopecia
Also known as
BAY-1158061, HMI115
Last public activity
June 2025
Record confidence
Medium

Why it matters

Mechanistically the most distinct programme in the register. If prolactin signalling turns out to matter in pattern hair loss, this is the only asset positioned to exploit it — and it would work on people for whom the DHT route has failed.

Development history

  1. Phase 1Phase 2

    First Phase 2 trial on record: NCT06118866 — A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

    ClinicalTrials.gov ↗
  2. Phase 1

    First Phase 1 trial on record: NCT05324293 — To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT06118866Phase 2COMPLETED

    A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

    Hope Medicine (Nanjing) Co., Ltd · n=192 · September 2023

  • NCT05324293Phase 1COMPLETED

    To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

    Hope Medicine (Nanjing) Co., Ltd · n=16 · May 2022

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources